€617.00 €524.45
Immunoglobulin A (IgA) is a member of the immunoglobulin superfamily of glycoproteins with roles in host defense against intestinal pathogens and both quantitative and qualitative control of host commensal microbiota composition.{53918,53919} It is produced by B cells and later secreted by plasma cells and is the most abundant antibody on mucosal surfaces that comprises at least 70% of all Ig produced in mice. Mouse IgA consists of two heavy chains of approximately 53.5 kDa each and two light chains of approximately 25 kDa each.{53917} Unlike human IgA, mouse IgA exists as a single isotype and is primarily found as a dimer that lacks the disulfide bonds between the light and heavy chains present in other Ig classes.{53917,53920} Production of IgA is induced in the gut only in animals containing intestinal microbes, and the number of IgA-producing plasma cells is reduced in germ-free mice.{53918} IgA-deficient mice exhibit increased lethality compared with wild-type mice in a model of influenza infection, as well as reduced parasite clearance in a model of G. muris infection. However, IgA deficiency does not affect clearance of vaginal infection with herpes simplex virus 2 (HSV-2), indicating redundancy in pathogen protection with compensation by antibodies of other isotypes or innate immune mechanisms at mucosal surfaces. Cayman’s IgA (mouse) Rabbit Monoclonal Antibody – Biotinylated can be used for ELISA and Western blot (WB; non-reducing conditions) applications. The antibody recognizes IgA from mouse samples.
Territorial Availability: Available through Bertin Technologies only in France
| Size | 50 µg |
|---|---|
| Shipping | dry ice |
| Molecular weight | 0 |
| Host | Rabbit |
| Antigen | Mouse IgA |
| Clone | RM220 |
| Isotype | IgG |
| Application(s) | ELISA, WB (non-reducing conditions) |
| Formulation | 50 µg of protein A-affinity purified monoclonal antibody |
| Custom code | 3822.19 |
| UNSPSC code | 12352203 |
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.
This mixture contains primary prostaglandins produced from arachidonic acid and dihomo-?-linolenic acid. Contents: Prostaglandin E1, Prostaglandin E2, Prostaglandin F1?, 6-keto...
To be used in conjunction with Cayman’s NAPE-PLD polyclonal antibody (aa 6-20) (Item No. 10306) to block protein-antibody complex formation...
This mixture contains the primary metabolites of prostaglandins (PGs) D2, E2, and F2?. Contents: 13,14-dihydro-15-keto PGD2, 13,14-dihydro-15-keto PGE2, 11?-PGF2?, 13,14-dihydro-15-keto...
Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère
78180 Montigny le Bretonneux
France
Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions
